Desensitization regimens for drug allergy: State of the art in the 21st century

Clinical and Experimental Allergy

Volumn 41, Issue 12, 2011, Pages 1679-1689

  Liu, A ^a   Fanning, L ^a   Chong, H ^a   Fernandez, J ^a   Sloane, D ^a   Sancho Serra, M ^a   Castells, M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMINOGLYCOSIDE; BETA N ACETYLHEXOSAMINIDASE; CARBOPLATIN; CEPHALOSPORIN; CIPROFLOXACIN; CISPLATIN; DIPHENHYDRAMINE; DOCETAXEL; FAMOTIDINE; IMMUNOGLOBULIN E; INFLIXIMAB; INTERLEUKIN 6; ISONIAZID; METRONIDAZOLE; OXALIPLATIN; PACLITAXEL; PENICILLIN G; PROSTAGLANDIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RITUXIMAB; SULFAMETHOXAZOLE; TRASTUZUMAB; TRIMETHOPRIM; TUMOR NECROSIS FACTOR; VANCOMYCIN;

BACKACHE; BASOPHIL; CARDIOVASCULAR SYMPTOM; CLINICAL PROTOCOL; CLINICAL SKIN REACTION; DESENSITIZATION; DISEASE MODEL; DRUG HYPERSENSITIVITY; DYSPNEA; FLUSHING; HEALTH CARE PERSONNEL; HEALTH PROGRAM; HISTORY; HUMAN; HYPERSENSITIVITY REACTION; HYPERTENSION; HYPOTENSION; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; MAST CELL; MEDICAL LITERATURE; NONHUMAN; OVARY CANCER; PATIENT SAFETY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SKIN TEST; THROAT TIGHTNESS; TRAINING; UBIQUITINATION; URTICARIA;

ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DESENSITIZATION, IMMUNOLOGIC; DRUG HYPERSENSITIVITY; HUMANS; ORGANOPLATINUM COMPOUNDS; TAXOIDS;

EID: 82155196443     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2011.03825.x     Document Type: Review

References (67)

1. Castells M. Desensitization for drug allergy. Curr Opin Allergy Clin Immunol 2006; 6:476-81.
2. Lee CW, Matulonis UA, Castells MC.Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses. Gynecol Oncol 2005; 99:393-9.
3. Castells MC, Tennant N, Sloane Det al. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 2008; 122:574-80.
4. Lee CW, Matulonis UA, Castells MC.Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions. Gynecol Oncol 2004; 95:370-6.
5. Kraft S, Kinet JP.New developments in FcepsilonRI regulation, function and inhibition. Nat Rev Immunol 2007; 7:365-78.
6. Gilfillan AM, Rivera J.The tyrosine kinase network regulating mast cell activation. Immunol Rev 2009; 228:149-69.
7. Shalit M, Levi-Schaffer F.Challenge of mast cells with increasing amounts of antigen induces desensitization. Clin Exp Allergy 1995; 25:896-902.
8. Kepley CL. Antigen-induced reduction in mast cell and basophil functional responses due to reduced Syk protein levels. Int Arch Allergy Immunol 2005; 138:29-39.
9. Morales AR, Shah N, Castells M.Antigen-IgE desensitization in signal transducer and activator of transcription 6-deficient mast cells by suboptimal doses of antigen. Ann Allergy Asthma Immunol 2005; 94:575-80.
10. Wendel GD Jr, Stark BJ, Jamison RB, Molina RD, Sullivan TJ. Penicillin allergy and desensitization in serious infections during pregnancy. N Engl J Med 1985; 312:1229-32.
11. Gadde J, Spence M, Wheeler B, Adkinson NF Jr. Clinical experience with penicillin skin testing in a large inner-city STD clinic. JAMA 1993; 270:2456-63.
12. Green GR, Rosenblum AH, Sweet LC.Evaluation of penicillin hypersensitivity: value of clinical history and skin testing with penicilloyl-polylysine and penicillin G.A cooperative prospective study of the penicillin study group of the American Academy of Allergy. J Allergy Clin Immunol 1977; 60:339-45.
13. Park MA, Li JT.Diagnosis and management of penicillin allergy. Mayo Clin Proc 2005; 80:405-10.
14. Salkind AR, Cuddy PG, Foxworth JW.The rational clinical examination. Is this patient allergic to penicillin? An evidence-based analysis of the likelihood of penicillin allergy. JAMA 2001; 285:2498-505.
15. Sogn DD, Evans R, Shephard Get al. Results of the National Institute of Allergy and Infectious Diseases Collaborative Clinical Trial to test the predictive value of skin testing with major and minor penicillin derivatives in hospitalized adults. Arch Intern Med 1992; 152:1025-32.
16. Park MA, Koch CAKlemawesch P, Joshi A, Li JT. Increased adverse drug reactions to cephalosporins in penicillin allergy patients with positive penicillin skin test. Int Arch Allergy Immunol153:268-73.
17. Kelkar PS, Li JT.Cephalosporin allergy. N Engl J Med 2001; 345:804-9.
18. Saxon A et al. Imipenem cross-reactivity with penicillin in humans. J Allergy Clin Immunol 1988; 82:213-7.
19. Romano A, Guéant-Rodriguez R, Gaeta F, Pettinato R, Guéant J. Imipenem in patients with immediate hypersensitivity to penicillins. N Engl J Med 2006; 354:2835-7.
20. Burrows JA, Toon M, Bell SC.Antibiotic desensitization in adults with cystic fibrosis. Respirology 2003; 8:359-64.
21. Legere HJ III, Palis RI, Rodriguez Bouza T, Uluer AZ, Castells MC. A safe protocol for rapid desensitization in patients with cystic fibrosis and antibiotic hypersensitivity. J Cyst Fibros 2009; 8:418-24.
22. Turvey SE, Cronin B, Arnold A, and Dioun F. Antibiotic desensitization for the allergic patient: 5 years of experience and practice. Ann Allergy Asthma Immunol 2004; 92:426-32.
23. Fruman DA, Wood MA, Gjertson CK, Katz HR, Burakoff SJ, Bierer BE. FK506 binding protein 12 mediates sensitivity to both FK506 and rapamycin in murine mast cells. Eur J Immunol 1900; 25:563-71.
24. Renz CL, Laroche D, Thurn Jet al. Tryptase levels are not increased during vancomycin-induced anaphylactoid reactions. Anesthesiology 1998; 89:620-5.
25. Anne S, Middleton EJr, Reisman RE.Vancomycin anaphylaxis and successful desensitization. Ann Allergy 1994; 73:402-4.
26. Kitazawa T, Ota Y, Kada Net al. Successful vancomycin desensitization with a combination of rapid and slow infusion methods. Intern Med 2006; 45:317-21.
27. Lin RY. Desensitization in the management of vancomycin hypersensitivity. Arch Intern Med 1990; 150:2197-8.
28. Wazny LD, Daghigh BDesensitization protocols for vancomycin hypersensitivity. Ann Pharmacother 2001; 35:1458-64.
29. Wong JT, Ripple R, Maclean J, Marks D, Bloch K. Vancomycin hypersensitivity: synergism with narcotics and "desensitization" by a rapid continuous intravenous protocol. J Allergy Clin Immunol 1994; 94(2, Part 1):189-94.
30. Gea-Banacloche JC, Metcalfe DD.Ciprofloxacin desensitization. J Allergy Clin Immunol 1996; 97:1426-7.
31. Shear NH, Speilberg SP, Grant DM, Tang BK, Kalow W. Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. Ann Intern Med 1986; 105:179-84.
32. Earl HS, Sullivan TJ.Acute desensitization of a patient with cystic fibrosis allergic to both beta-lactam and aminoglycoside antibiotics. J Allergy Clin Immunol 1987; 79:477-83.
33. Spigarelli MG, Hurwitz ME, Nasr SZ.Hypersensitivity to inhaled TOBI following reaction to gentamicin. Pediatr Pulmonol 2002; 33:311-4.
34. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KDet al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 1994; 12:2654-66.
35. Kwon JS, Elit L, Finn Met al. A comparison of two prophylactic regimens for hypersensitivity reactions to paclitaxel. Gynecol Oncol 2002; 84:420-5.
36. Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center. J Clin Oncol 2000; 18:102-5.
37. Wiernik PH, Schwartz E, Strauman J, Dutcher J, Lipton R, Paietta E. Phase I clinical and pharmacokinetic study of taxol. Cancer Res 1987; 47:2486-93.
38. Schrijvers D, Wanders J, Dirix Let al. Coping with toxicities of docetaxel (Taxotere). Ann Oncol 1993; 4:610-1.
39. Weiss RB, Donehower RC, Wiernik PHet al. Hypersensitivity reactions from taxol. J Clin Oncol 1990; 8:1263-8.
40. Brennan PJ, Bouza T, Hsu FI, Sloane D, Castells M. Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment. J Allergy Clin Immunol 2009; 124:1259-66.
41. Lokich J, Anderson N.Paclitaxel hypersensitivity reactions: a role for docetaxel substitution. Ann Oncol 1998; 9:573.
42. Moon C, Verschraegen CF, Bevers M, Freedman R, Kudelka AP, Kavanagh. Use of docetaxel (Taxotere) in patients with paclitaxel (Taxol) hypersensitivity. Anticancer Drugs 2000; 11:565-8.
43. Dizon DS, Schwartz J, Rojan Aet al. Cross-sensitivity between paclitaxel and docetaxel in a women's cancers program. Gynecol Oncol 2006; 100:149-51.
44. Price KS, Castells MC.Taxol reactions. Allergy Asthma Proc 2002; 23:205-8.
45. Decorti G et al. Effect of paclitaxel and Cremophor EL on mast cell histamine secretion and their interaction with adriamycin. Anticancer Res 1996; 16:317-20.
46. Eschalier A, Lavarenne J, Burtin C, Renoux M, Chapuy E. Study of histamine release induced by acute administration of antitumor agents in dogs. Cancer Chemother Pharmacol 1988; 21:246-50.
47. Essayan DM, Kagey-Sobotka A, Colarusso P, Lichtenstein L, Ozols R, and King E. Successful parenteral desensitization to paclitaxel. J Allergy Clin Immunol 1996; 97(1, Part 1):42-6.
48. Szebeni J, Muggia FM, Alving CR.Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J Natl Cancer Inst 1998; 90:300-6.
49. Feldweg AM, Lee CW, Matulonis UA, and Castells M. Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments. Gynecol Oncol 2005; 96:824-9.
50. Aabo K., Adams M., Adnitt P.et al. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group. Br J Cancer 1998; 78:1479-87.
51. Gomez R, Harter P, Lück HJet al. Carboplatin hypersensitivity: does introduction of skin test and desensitization reliably predict and avoid the problem? A prospective single-center study. Int J Gynecol Cancer 2009; 19:1284-7.
52. Gadducci A, Tana R, Teti G, Zanca G, Fanucchi A, Genazzani AR. Analysis of the pattern of hypersensitivity reactions in patients receiving carboplatin retreatment for recurrent ovarian cancer. Int J Gynecol Cancer 2008; 18:615-20.
53. Makrilia N, Syrigou E, Kaklamanos I, Manolopoulos L, Wasif Saif M. Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. Met Based Drugs 2010; 2010, 207084, 11 pp.
54. Markman M, Kennedy A, Webster Ket al. Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol 1999; 17:1141.
55. Navo M, Kunthur A, Badell Met al. Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients. Gynecol Oncol 2006; 103:608-13.
56. Maindrault-Goebel F, André T, Tournigand Cet al. Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients. Eur J Cancer 2005; 41:2262-7.
57. Lee C, Gianos M, Klaustermeyer WB.Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents. Ann Allergy Asthma Immunol 2009; 102:179-87; quiz 187-9, 222.
58. Schwartz JR, Bandera C, Bradley Aet al. Does the platinum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin? The experience from Women and Infants' Hospital. Gynecol Oncol 2007; 105:81-3.
59. Markman M, Zanotti K, Peterson G, Kulp B, Webster K, Belinson J. Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity. J Clin Oncol 2003; 21:4611-4.
60. Kim BH, Bradley T, Tai J, Budman DR. Hypersensitivity to oxaliplatin: an investigation of incidence and risk factors, and literature review. Oncology 2009; 76:231-8.
61. Polyzos A, Tsavaris N, Kosmas Cet al. Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience. Oncology 2001; 61:129-33.
62. Dizon DS, Sabbatini PJ, Aghajanian C, Hensley ML, Spriggs DR. Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy. Gynecol Oncol 2002; 84:378-82.
63. O'Cearbhaill R, Zhou Q, Iasonos Aet al. The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment. Gynecol Oncol116:326-31.
64. Chung CH, O'Neil BH.Infusion reactions to monoclonal antibodies for solid tumors: immunologic mechanisms and risk factors. Oncology (Williston.Park) 2009; 23:14-7.
65. Kang SP, Saif MW.Infusion-related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer - identification, prevention, and management. J Support Oncol 2007; 5:451-7.
66. O'Neil BH, Allen R, Spigel DRet al. High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. J Clin Oncol 2007; 25:3644-8.
67. Sancho-Serra M, Simarro M, Castells M. Rapid IgE desensitization is antigen specific and impairs early and late most cell responses targeting FCe{open}RI internalization. Eur J Immunol 2011; 41:1004-13.